Jeena Sikho Lifecare Q2 FY27: Rev ₹224.4 Cr

Investor Takeaways

Revenue grew 29% YoY to ₹224.4 crore in Q1 FY27.

Government-panel IPD revenue declined 67% YoY to ₹5.2 crore.

Private-pay IPD revenue grew 26% YoY to ₹84.8 crore.

Services revenue grew 13% YoY to ₹106.0 crore.

Market Cap: ₹7,944.06 Cr; P/E Ratio: 36.03.

Overall Tone: Neutral based on the numbers only.

Key Financial Highlights

Metric	Value	YoY Change
Revenue	₹224.4 Cr	29%
Net Profit	Not available	N/A
EBITDA	Not available	N/A
EPS	Not available	N/A
OPM	Not available	N/A

What Changed

The filing reveals a clear strategic shift in revenue composition. Total revenue increased 29% YoY to ₹224.4 crore, driven entirely by growth in private-pay segments. Government-panel IPD revenue collapsed 67% YoY to ₹5.2 crore, while private-pay IPD revenue expanded 26% to ₹84.8 crore. Services revenue also grew steadily at 13% YoY to ₹106.0 crore. This indicates successful diversification away from lower-margin government contracts toward higher-quality private-pay revenue streams. The company demonstrated improved cash conversion through this shift, though absolute profitability metrics (net profit, EBITDA, OPM) were not disclosed in the provided data. The market cap of ₹7,944.06 Cr and P/E of 36.03 reflect investor pricing of this growth trajectory.

Peer Comparison

Company	P/E	ROE	ROCE	Market Cap (₹ Cr)
Jeena Sikho Lifecare Limited (JSLL)	36.03	N/A	N/A	7,944.06
Avenue Supermarts Limited (DMART)	104.25	N/A	N/A	2,84,258.63
ETERNAL LIMITED (ETERNAL)	317.34	N/A	N/A	2,32,747.16
Trent Limited (TRENT)	75.43	N/A	N/A	1,45,796.38

JSLL trades at a significant discount to peers like DMART and Trent on P/E basis, though higher than ETERNAL. The company's valuation appears more aligned with growth-oriented peers despite operating in a different segment of consumer services.

Risks & Concerns

Government-panel IPD revenue declined 67% YoY to ₹5.2 crore, indicating vulnerability to public sector budgetary changes or contract renewals.

No profitability metrics (net profit, EBITDA, OPM) were disclosed in the provided data, limiting assessment of margin trends.

Revenue growth was heavily reliant on private-pay IPD (26% growth), which may face competitive pressures or demand saturation.

Quarterly Trend

Not available

📄 View Original Announcement (PDF)

📊 Stock Analysis — JSLL ✨ Ask AI About This

About Jeena Sikho Lifecare Limited (JSLL)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹6,347.42 Cr P/E: 26.9 ROE: 187.8% ROCE: 261.5% Div Yield: 0.88%

View full JSLL stock details →

📡 Get AI alerts when JSLL files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track JSLL — Free

💡 Ask AI about this filing

"How does private-pay IPD growth compare to government-panel trends?" "What is the expected impact of declining government-panel revenue on margins?" "When will next quarter's financials be released?"

Ask AI Free →

📊 More JSLL filings

See all JSLL filings →

🔥 Also filed on 20 August 2026

ANURAS Anupam Rasayan India Limited Financial Results SUPRAJIT Suprajit Engineering Limited Annual Report NIRAJ Niraj Cement Structurals Limited Announcement PNBHOUSING PNB Housing Finance Limited Corporate Action KRONOX Kronox Lab Sciences Limited Announcement SHRIPISTON SPR Auto Technologies Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when JSLL files new disclosures

Track JSLL filings, board meetings, and corporate actions. Free email alerts at 5 PM.